Clinical Trial Update: Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

This Phase 1 study update reports on the safety and pharmacokinetics of XL147 (SAR245408) in adults with solid tumors or lymphoma, sponsored by Sanofi.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lymphoma

Drugs mentioned

• XL147 (SAR245408) (XL147)

Snippet

Sponsor: Sanofi | Conditions: Cancer, Lymphoma | Phase 1 | Status: COMPLETED